IL5RA and acute myeloid leukemia: <b>Conclusions:</b> These findings provide preliminary proof-of-concept evidence that IL-5Rα targeting by Benralizumab may directly affect cell survival and cell cycle regulation in AML cells with promyelocytic characteristics.